SmartNuclide Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $14.1M
Latest Deal Amount
  • Investors
  • 3

SmartNuclide General Information

Description

Developer and researcher of biopharmaceuticals for molecular nuclear oncology. The company specializes in developing innovative biological drug products including both diagnostics and therapeutics formulations targeting molecular oncology, providing reliable and effective products for better cancer treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 218 Xinghu Street, BioBAY A4-202
  • Suzhou Industrial Park
  • Suzhou, Jiangsu
  • China

SmartNuclide Timeline

2017201820192020
Financing RoundFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SmartNuclide Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 23-Apr-2020 $14.1M 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 12-Nov-2018 Completed Generating Revenue
1. Early Stage VC 21-Mar-2016 Completed Startup
To view SmartNuclide’s complete valuation and funding history, request access »

SmartNuclide Executive Team (1)

Name Title Board Seat Contact Info
Tao Xu Chief Executive Officer
To view SmartNuclide’s complete executive team members history, request access »

SmartNuclide Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Jiuyou Capital Venture Capital Minority 000 0000 000000 0
Longmen Capital Venture Capital Minority 000 0000 000000 0
BOHE Angel Fund Venture Capital Minority 000 0000 000000 0
To view SmartNuclide’s complete investors history, request access »